Readline, a Shenzhen-based bio-pharmaceutical firm, has secured 300 million yuan ($43 million) in a Series B round led by CoStone Capital, the firm announced via its WeChat channel on Friday.
The round, participated by institutional investors such as Jinhang Group, Gree Electric, Xinshang Capital, Oriental Fortune Capital, Green Pine Capital Partners, and Hunan Caixin Investment Holding Group, will help the firm to invest into its R&D platform, as well as ramp up hires, per the release.